Literature DB >> 5819167

Rifampicin desacetylation in the human organism.

N Maggi, S Furesz, R Pallanza, G Pelizza.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5819167

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


× No keyword cloud information.
  9 in total

1.  Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance.

Authors:  W Zilly; D D Breimer; E Richter
Journal:  Eur J Clin Pharmacol       Date:  1975-12-19       Impact factor: 2.953

2.  Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid.

Authors:  G Boman
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

3.  Rifampicin in plasma and pleural fluid after single oral doses.

Authors:  G Boman; A S Malmborg
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

Review 4.  Clinical pharmacokinetic considerations in the treatment of patients with leprosy.

Authors:  K Venkatesan
Journal:  Clin Pharmacokinet       Date:  1989-06       Impact factor: 6.447

5.  Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease.

Authors:  G Acocella; L Bonollo; M Garimoldi; M Mainardi; L T Tenconi; F B Nicolis
Journal:  Gut       Date:  1972-01       Impact factor: 23.059

6.  Pharmacokinetic interactions with rifampicin.

Authors:  W Zilly; D D Breimer; E Richter
Journal:  Clin Pharmacokinet       Date:  1977 Jan-Feb       Impact factor: 6.447

7.  A case of fatal poisoning by rifampicin.

Authors:  T A Plomp; H J Battista; H Unterdorfer; W C van Ditmarsch; R A Maes
Journal:  Arch Toxicol       Date:  1981-11       Impact factor: 5.153

Review 8.  A review of the Redman syndrome and rifampicin overdosage.

Authors:  M R Holdiness
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Nov-Dec

Review 9.  Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure.

Authors:  Vincent Launay-Vacher; Hassane Izzedine; Gilbert Deray
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.